BioNexus Gene Lab Corp (BGLC) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 24.5 (OVERSOLD (<32))
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 14.6% Gross Margin
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While BGLC currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.35) and Max Pain ($1.03) forces dealer call-delta covering toward $5.95.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
BioNexus Gene Lab Corp (BGLC) dropped -7.79% to $0.98, trading at 2% of its 52-week range ($0.88 – $5.67). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Redesigned site brings together information on BGLC’s operating businesses, healthcare initiatives and public disclosuresKUALA LUMPUR, Malaysia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -21.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BGLC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BGLC. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, BioNexus Gene Lab Corp (BGLC) ranks #949 by composite RQD confidence (30/100, grade E) and #982 by equity capitalization ($2.9M). Within this direct 5-issuer industry benchmark cohort, BGLC leads on earnings valuation at N/A trailing P/E, while ADVB leads on capital efficiency and profitability with -9.1% ROIC and — gross margin. SERA currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with BGLC at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BGLC
ACTIVE
BioNexus Gene Lab Corp | E | 30/100 | — | 14.6% | -35.0% | -7.79% | $2.9M | Benchmark Subject |
| ADVB Advanced Biomed Inc. | E | 32/100 | — | — | -9.1% | -11.41% | $4.4M | /advb-vs-bglc → |
| ACON Aclarion Inc. | E | 24/100 | — | 9.0% | -35.0% | -3.43% | $5.7M | /acon-vs-bglc → |
| AMS American Shared Hospital Services | E | 29/100 | — | 18.0% | -13.8% | -5.26% | $8.4M | /ams-vs-bglc → |
| SERA Sera Prognostics Inc. (Class A) | D- | 40/100 | — | -30.0% | -35.0% | +1.48% | $81.3M | /sera-vs-bglc → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), BioNexus Gene Lab Corp (BGLC) reported GAAP revenue of $7.4M (-21.9% vs. FY2024 revenue of $9.5M , and -24.0% cumulative change since FY2023) , GAAP net income of -$3.0M, operating cash flow of -$1.8M, and free cash flow of -$1.9M (+19.2% YoY). On the balance sheet, BGLC closed FY2025 with $9.3M in total assets against $0 in total debt (Altman Z-Score: 2.12, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $7.4M | -$3.0M | -$1.8M | -$1.9M | $9.3M | — |
| FY2024 (FY) | 2024-12-31 | $9.5M | -$1.6M | -$2.1M | -$2.3M | $10.4M | — |
| FY2023 (FY) | 2023-12-31 | $9.8M | -$2.6M | -$1.8M | -$1.8M | — | — |
As of 2026-11-01, BioNexus Gene Lab Corp (NASDAQ: BGLC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $0.98 (-7.79% 1D, market cap $2.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BGLC ranks #949 in composite RQD confidence.
Within the Health Care sector (Medical Specialities), BGLC carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 14.6%, and ROIC of -35.0%. By comparison, ADVB (Advanced Biomed Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -9.1%, cap $4.4M) and ACON (Aclarion Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $5.7M). Among the 5-stock peer group, BGLC leads on earnings multiple (N/A) while ADVB leads on capital efficiency (-9.1% ROIC).
Per BGLC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001737523), BioNexus Gene Lab Corp generated $7.4M in revenue (-21.9% YoY), -$3.0M in net income, and -$1.9M in free cash flow against $9.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
BGLC last traded at $0.98 (-7.79% on volume of 4,147 shares), positioning the stock -27.41% below its 50-day simple moving average ($1.35) and -50.00% below its 200-day simple moving average ($1.96). Across its 52-week range of $0.88 to $5.67, BGLC sits at the 2.1% percentile with a 14-day RSI of 24.5 (OVERSOLD (<32)) and an implied next-earnings move of ±10.6% ($1.00 to $1.08).
Why BGLC Stock dropped -7.79% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.